Aspen Pharmacare Holdings guides FY NHEPS continuing ops between ZAR 7.84-8.17 vs year-ago ZAR 6.59 and FactSet ZAR7.54 (ZAR 144.95, +1.31)
Positive CHMP opinion by the EMA supports broader use of Amgen's REPATHA before a first heart attack or stroke ($393.10, 0.00)
Merck announces initial access plans for Alimatravir ($130.48, 0.00)
EU's CHMP adopted positive opinion recommending change to terms of marketing authorisation for medicinal product Repatha ($371.50, 0.00)
Aspen Pharmacare Canada Inc. receives regulatory approval from Health Canada for Aspen-Semaglutidel (ZAR 151.82, +1.50)
Aspen Pharmacare Holdings announces Kuseni Dlamini will step down as Chair of the Board at AGM in Dec-26 (ZAR 148.55, -1.85)
Amgen présente de nouvelles données lors des 86e Sessions Scientifiques de l’American Diabetes Association (ADA), incluant les résultats de sous-groupes de l’étude de phase 3 VESALIUS-CV ($349.58, 0.00)
Amgen presents new data at the American Diabetes Association (ADA) 86th Scientific Sessions including Phase 3 VESALIUS-CV subgroup results ($349.58, 0.00)
Aspen Pharmacare Holdings completes the divestment of Aspen APAC (ZAR 134.75, 0.00)
StreetAccount M&A Summary: Week of 20-Apr
Powered by FactSet Research Systems Inc.